University of Texas Texas AM Investment Management Co. Invests $920,000 in Catalyst Pharmaceuticals, Inc. $CPRX

University of Texas Texas AM Investment Management Co. bought a new position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) in the 4th quarter, Holdings Channel reports. The fund bought 39,435 shares of the biopharmaceutical company’s stock, valued at approximately $920,000.

Several other hedge funds have also made changes to their positions in the business. Parkside Financial Bank & Trust boosted its stake in shares of Catalyst Pharmaceuticals by 17.6% during the fourth quarter. Parkside Financial Bank & Trust now owns 3,138 shares of the biopharmaceutical company’s stock worth $73,000 after buying an additional 469 shares during the period. Oregon Public Employees Retirement Fund boosted its stake in shares of Catalyst Pharmaceuticals by 1.8% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 26,428 shares of the biopharmaceutical company’s stock worth $617,000 after buying an additional 472 shares during the period. Jones Financial Companies Lllp boosted its stake in shares of Catalyst Pharmaceuticals by 14.0% during the third quarter. Jones Financial Companies Lllp now owns 4,061 shares of the biopharmaceutical company’s stock worth $79,000 after buying an additional 498 shares during the period. Lifestyle Asset Management Inc. boosted its stake in shares of Catalyst Pharmaceuticals by 3.4% during the fourth quarter. Lifestyle Asset Management Inc. now owns 16,835 shares of the biopharmaceutical company’s stock worth $393,000 after buying an additional 553 shares during the period. Finally, Smartleaf Asset Management LLC boosted its stake in shares of Catalyst Pharmaceuticals by 55.6% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,764 shares of the biopharmaceutical company’s stock worth $41,000 after buying an additional 630 shares during the period. Institutional investors and hedge funds own 79.22% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the stock. Citigroup downgraded shares of Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $35.00 to $31.50 in a research note on Friday, May 8th. Weiss Ratings upgraded shares of Catalyst Pharmaceuticals from a “buy (b-)” rating to a “buy (b)” rating in a research note on Wednesday, June 3rd. Cantor Fitzgerald upgraded shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a research note on Friday, March 27th. Zacks Research downgraded shares of Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Monday, May 18th. Finally, Stephens set a $32.00 target price on shares of Catalyst Pharmaceuticals in a research note on Thursday, May 7th. Two investment analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat, Catalyst Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $32.00.

Catalyst Pharmaceuticals Stock Up 0.0%

NASDAQ CPRX opened at $31.37 on Tuesday. The stock has a market capitalization of $3.84 billion, a P/E ratio of 18.03, a P/E/G ratio of 0.95 and a beta of 0.74. Catalyst Pharmaceuticals, Inc. has a 52-week low of $19.05 and a 52-week high of $32.56. The firm has a 50-day moving average price of $29.29 and a 200 day moving average price of $25.70.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).